At a glance
ClinicalIndex Comparison RecordN/ACompleted· 124 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Placebo 0mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes
In Brief
A clinical study evaluating Placebo and Aliskiren for Diabetes Type 2. Completed, enrolled 124 participants across 1 site.
Detailed Summary
The purpose of this research is to study and determine the effects of Aliskiren on blood vessels and blood flow. The primary hypothesis is that Aliskiren will increase endothelial function by 30% or more in comparison to the placebo group.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Type 2
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
First PostedJul 2010
Primary CompletionJan 2012
TodayJul 2026
First PostedJul 20, 2010
Enrollment StartNov 1, 2009
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 16.0 years ago
Interventions
Placebodrug
0mg tablet, taken orally for 12 weeks daily
Aliskirendrug
150mg tablet, taken orally for 12 weeks daily